AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Thiamine Deficiency: Fursultiamine hydrochloride is primarily used to treat thiamine deficiency, which can occur due to inadequate dietary intake, malabsorption disorders, chronic alcoholism, or certain medical conditions. Thiamine deficiency can lead to symptoms such as fatigue, weakness, neurological problems, and cardiovascular abnormalities. Fursultiamine hydrochloride supplementation helps restore thiamine levels in the body and alleviates deficiency-related symptoms.
Improved Energy Metabolism: Thiamine is essential for the metabolism of carbohydrates, fats, and proteins, playing a crucial role in cellular energy production. Fursultiamine hydrochloride supplementation can enhance energy metabolism by facilitating the conversion of nutrients into usable energy for various physiological processes. This may result in improved energy levels and overall well-being, particularly in individuals with thiamine deficiency.
Neurological Benefits: Thiamine is important for proper neurological function, and thiamine deficiency can manifest as neurological symptoms such as neuropathy, weakness, and cognitive impairment. Fursultiamine hydrochloride supplementation helps maintain optimal thiamine levels in the nervous system, which may support nerve function and reduce the risk of neurological complications associated with thiamine deficiency.
Cardiovascular Health: Thiamine plays a role in cardiovascular function, and thiamine deficiency can lead to heart-related complications such as congestive heart failure and cardiac arrhythmias. By replenishing thiamine levels, fursultiamine hydrochloride supplementation may support cardiovascular health and reduce the risk of heart-related complications in individuals with thiamine deficiency.
Alleviation of Fatigue and Weakness: Thiamine deficiency can cause symptoms such as fatigue, weakness, and muscle pain due to impaired energy metabolism and neuromuscular function. Fursultiamine hydrochloride supplementation helps address these symptoms by restoring thiamine levels and improving cellular energy production, thereby promoting vitality and physical endurance.
Treatment of Wernicke-Korsakoff Syndrome: Wernicke-Korsakoff syndrome is a neurological disorder caused by severe thiamine deficiency, often associated with chronic alcoholism. Fursultiamine hydrochloride may be used as part of the treatment regimen for Wernicke-Korsakoff syndrome to replenish thiamine levels and alleviate neurological symptoms.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 2.6 | 0.4 | 5.5 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
Allergic Rhinitis (Hay Fever) | 1 | 1.6 | -0.6 |
Allergies | 3.5 | 1.8 | 0.94 |
Allergy to milk products | 0.8 | 0.4 | 1 |
Alopecia (Hair Loss) | 1.2 | 1.2 | |
Alzheimer's disease | 1.7 | 2.4 | -0.41 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.4 | 2.25 |
Ankylosing spondylitis | 2.5 | 0.7 | 2.57 |
Anorexia Nervosa | 1.1 | -1.1 | |
Antiphospholipid syndrome (APS) | 1 | 1 | |
Asthma | 1.3 | 0.3 | 3.33 |
Atherosclerosis | 0.9 | 1.1 | -0.22 |
Atrial fibrillation | 2 | 0.7 | 1.86 |
Autism | 6 | 4.5 | 0.33 |
Barrett esophagus cancer | 0.5 | 0.1 | 4 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.4 | 1.1 | -1.75 |
Brain Trauma | 0.8 | 0.2 | 3 |
Carcinoma | 2.5 | 2 | 0.25 |
Celiac Disease | 1.3 | 2.4 | -0.85 |
Cerebral Palsy | 1.2 | 0.7 | 0.71 |
Chronic Fatigue Syndrome | 3.9 | 3.9 | 0 |
Chronic Kidney Disease | 1.1 | 0.7 | 0.57 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.2 | 3 |
Chronic Urticaria (Hives) | 1.1 | 0.3 | 2.67 |
Coagulation / Micro clot triggering bacteria | 0.4 | 0.7 | -0.75 |
Colorectal Cancer | 1.5 | 0.8 | 0.88 |
Constipation | 0.5 | 0.5 | 0 |
Coronary artery disease | 1 | 0.9 | 0.11 |
COVID-19 | 8.7 | 8.2 | 0.06 |
Crohn's Disease | 4.5 | 2.4 | 0.88 |
cystic fibrosis | 0.3 | 0.5 | -0.67 |
deep vein thrombosis | 0.3 | 0.3 | 0 |
Depression | 5.4 | 4.2 | 0.29 |
Dermatomyositis | 0.1 | 0.3 | -2 |
Eczema | 0.9 | 1 | -0.11 |
Endometriosis | 1.7 | 0.8 | 1.13 |
Eosinophilic Esophagitis | 0 | 0.4 | 0 |
Epilepsy | 1.6 | 0.9 | 0.78 |
Fibromyalgia | 1.9 | 1.5 | 0.27 |
Functional constipation / chronic idiopathic constipation | 2.5 | 1.5 | 0.67 |
gallstone disease (gsd) | 1.8 | 0.5 | 2.6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.8 | 0 |
Generalized anxiety disorder | 1.1 | 1.3 | -0.18 |
giant cell arteritis | 0.4 | -0.4 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 0.1 | -0.1 | |
Graves' disease | 0.9 | 1.3 | -0.44 |
Halitosis | 0.6 | 0.1 | 5 |
Hashimoto's thyroiditis | 1.5 | 0.4 | 2.75 |
Hidradenitis Suppurativa | 0.1 | 0.4 | -3 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.8 | 0.5 | 2.6 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.1 | 5 |
hyperglycemia | 0.1 | 0.9 | -8 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.4 | 1 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 1.2 | 2.6 | -1.17 |
Hypothyroidism | 1.1 | -1.1 | |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 2.3 | -2.3 | |
Inflammatory Bowel Disease | 2.8 | 3.6 | -0.29 |
Insomnia | 0.6 | 0.2 | 2 |
Intelligence | 0.7 | 0.2 | 2.5 |
Intracranial aneurysms | 0.6 | 0.4 | 0.5 |
Irritable Bowel Syndrome | 2.5 | 1.9 | 0.32 |
Liver Cirrhosis | 2.8 | 2.1 | 0.33 |
Long COVID | 5.1 | 6 | -0.18 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.2 | 1 | -4 |
ME/CFS with IBS | 0.9 | 2.2 | -1.44 |
ME/CFS without IBS | 1.9 | 1.6 | 0.19 |
Menopause | 1.5 | 1.5 | |
Metabolic Syndrome | 4.8 | 4.6 | 0.04 |
Mood Disorders | 7.7 | 4.5 | 0.71 |
multiple chemical sensitivity [MCS] | 0.7 | 0.4 | 0.75 |
Multiple Sclerosis | 3 | 1.8 | 0.67 |
Multiple system atrophy (MSA) | 0.5 | 0.8 | -0.6 |
Neuropathy (all types) | 0.5 | 0.1 | 4 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.9 | 3.4 | -0.79 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 5.5 | 2.4 | 1.29 |
obsessive-compulsive disorder | 3 | 2.3 | 0.3 |
Osteoarthritis | 1.7 | 0.1 | 16 |
Osteoporosis | 1.4 | 0.6 | 1.33 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 1.6 | 1.6 | 0 |
Polycystic ovary syndrome | 1.4 | 1.3 | 0.08 |
Postural orthostatic tachycardia syndrome | 0.4 | 0.4 | 0 |
Premenstrual dysphoric disorder | 1.1 | 1.1 | |
primary biliary cholangitis | 0.4 | 0.7 | -0.75 |
Psoriasis | 3.7 | 0.6 | 5.17 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 2.6 | 0.58 |
Rosacea | 0.6 | 0.5 | 0.2 |
Schizophrenia | 5.2 | 1.4 | 2.71 |
scoliosis | 0.1 | 0.1 | 0 |
Sjögren syndrome | 2.2 | 2.4 | -0.09 |
Sleep Apnea | 1 | 1 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.4 | -0.33 |
Stress / posttraumatic stress disorder | 1.6 | 1.8 | -0.13 |
Systemic Lupus Erythematosus | 2.3 | 1.1 | 1.09 |
Tic Disorder | 0.6 | 1.3 | -1.17 |
Tourette syndrome | 0 | 0.1 | 0 |
Type 1 Diabetes | 1.9 | 1.7 | 0.12 |
Type 2 Diabetes | 4.8 | 3.6 | 0.33 |
Ulcerative colitis | 1.9 | 2.4 | -0.26 |
Unhealthy Ageing | 2.7 | 0.8 | 2.38 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.